Partners Capital Investment Group LLP Invests $566,000 in Urogen Pharma $URGN

Partners Capital Investment Group LLP purchased a new position in shares of Urogen Pharma (NASDAQ:URGN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 15,384 shares of the company’s stock, valued at approximately $566,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Algert Global LLC boosted its holdings in Urogen Pharma by 70.4% in the 2nd quarter. Algert Global LLC now owns 32,350 shares of the company’s stock valued at $1,190,000 after purchasing an additional 13,360 shares during the period. Quantbot Technologies LP bought a new position in shares of Urogen Pharma during the second quarter worth approximately $78,000. BlackRock Inc. acquired a new stake in shares of Urogen Pharma in the second quarter valued at approximately $117,814,000. Deutsche Bank AG acquired a new stake in shares of Urogen Pharma in the second quarter valued at approximately $1,897,000. Finally, Rice Hall James & Associates LLC bought a new stake in shares of Urogen Pharma in the second quarter valued at approximately $11,064,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

Insider Activity

In other news, insider Mark Schoenberg sold 60,677 shares of the stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $47.05, for a total value of $2,854,852.85. Following the completion of the transaction, the insider directly owned 59,086 shares in the company, valued at approximately $2,779,996.30. This represents a 50.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 85,899 shares of company stock worth $3,747,513 in the last three months. 4.80% of the stock is currently owned by corporate insiders.

Urogen Pharma Trading Down 1.5%

Shares of Urogen Pharma stock opened at $46.16 on Tuesday. The firm has a market capitalization of $2.26 billion, a PE ratio of -23.31 and a beta of 1.57. The firm’s 50 day moving average is $40.82 and its 200 day moving average is $29.32. Urogen Pharma has a 1 year low of $15.86 and a 1 year high of $50.81.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $72.46 million for the quarter, compared to analyst estimates of $63.55 million. As a group, research analysts anticipate that Urogen Pharma will post -0.2 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on URGN shares. Oppenheimer increased their price target on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. UBS Group reaffirmed a “buy” rating on shares of Urogen Pharma in a research note on Thursday, July 9th. HC Wainwright upped their price objective on shares of Urogen Pharma from $45.00 to $75.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. TD Cowen increased their price objective on shares of Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, LADENBURG THALM/SH SH started coverage on shares of Urogen Pharma in a report on Monday, May 11th. They issued a “buy” rating and a $43.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $50.38.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.